Core Insights - Arrowhead Pharmaceuticals is an RNAi company with a broad platform for delivering therapies to various tissues [2][3] - The company is currently developing 20 individual drug candidates that are either in clinical studies or on the market by the end of this year [3] - Arrowhead Pharmaceuticals is approaching its first PDUFA date on November 18, marking a potential transition from an R&D-only company to one that also engages in commercial activities [3]